Last reviewed · How we verify
Flu Vaccine
Flu Vaccine is a marketed influenza immunization product developed by La Fundacion Favaloro para la Investigacion y la Docencia Medica, designed to prevent infection from influenza A and B virus subtypes contained within the formulation. With 100 clinical trials and 1,164 publications supporting its development and use, the vaccine represents an established preventive therapy in the influenza market. As a marketed product, it has demonstrated clinical utility in seasonal influenza prevention across diverse populations. The vaccine's extensive publication record underscores its role in public health and clinical practice. Commercial significance is driven by annual seasonal demand and potential pandemic preparedness applications. The product maintains relevance through ongoing epidemiological surveillance and vaccine strain updates.
At a glance
| Generic name | Flu Vaccine |
|---|---|
| Also known as | Fluzone HD, Fluad Tetra, FLUAD QUADRIVALENT, Fluad Quad |
| Sponsor | La Fundacion Favaloro para la Investigacion y la Docencia Medica |
| Drug class | Prophylactic vaccine |
| Target | Influenza A and B viral hemagglutinin and neuraminidase surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of influenza caused by virus subtypes A and B contained in the vaccine
Common side effects
Drug interactions
- Immunosuppressants
- Aspirin or other salicylates
- Antiviral medications (e.g., oseltamivir, zanamivir)
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- Opioid, HIV and Immune System (PHASE4)
- Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |